Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
September 8, 2020

Pfizer, BioNTech get German approval for second Covid-19 vaccine trial

Pfizer and BioNTech have secured regulatory approval from the Paul-Ehrlich-Institut in Germany to conduct a Phase II/III clinical trial of their Covid-19 vaccine candidate, BNT162b2.

Pfizer and BioNTech have secured regulatory approval from the Paul-Ehrlich-Institut in Germany to conduct a Phase II/III clinical trial of their Covid-19 vaccine candidate, BNT162b2.

BNT162b2, which encodes an optimised SARS-CoV-2 full-length spike glycoprotein (S), is part of the companies’ BNT162 programme focused on Covid-19.

The BNT162 programme leverages BioNTech’s mRNA technology and Pfizer’s global vaccine development and manufacturing capabilities.

BNT162b1 and BNT162b2, two of the partners’ four investigational vaccine candidates, obtained fast track designation from the US Food and Drug Administration (FDA).

The new trial of BNT162b2 in Germany is part of the global pivotal Phase II/III programme launched by BioNTech and Pfizer in July this year.

It is designed to assess the safety and efficacy of the vaccine candidate in up to 30,000 participants aged 18 to 85 years. Volunteers will be given BNT162b2 or placebo at about 120 sites worldwide.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

So far, the trial enroled more than 25,000 participants, said BioNTech.

BioNTech CEO and co-founder Ugur Sahin said: “A large, controlled Phase III study is a crucial prerequisite to prove the safety and efficacy of a vaccine. The integration of sites in Europe, and now especially in Germany, is aimed at supporting an approval in Europe.”

If successful in clinical trials, Pfizer and BioNTech plan to seek regulatory approval for BNT162b2 Covid-19 vaccine as early as October this year.

After potential regulatory authorisation or approval, the companies aim to supply up to 100 million doses globally by the end of this year and about 1.3 billion doses by the end of next year.

In July this year, the companies initiated a Phase II/III trial of BNT162b2 at a 30µg dose level in a two-dose regimen, in the US.

The partners decided to advance the vaccine candidate into Phase II/III trials based on a review of preclinical and clinical data from Phase I/II studies.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU